A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

RecruitingOBSERVATIONAL

Enrollment

504

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions

Gastric CancerRWSPD-1 Immunotherapy

Interventions

DRUG

Camrelizumab

200mg,iv,d1,Q2W/Q3W

DRUG

apatinib

250mg,qd

DRUG

chemotherapy

Standard treatment

Trial Locations (1)

RECRUITING

Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi

All Listed Sponsors

lead

Changzhi People's Hospital Affiliated to Changzhi Medical College

OTHER